TAILIN BIOTECH(SZ:300813) 仪器信息网·2025-05-01 09:53Core Viewpoint - TaiLin Bio's revenue for 2024 is 349 million, an increase of 29.33%, while net profit decreased by 33.65% [1][3]. Financial Performance - Total revenue for 2024 reached 348,998,253.03 yuan, up from 269,856,059.81 yuan in 2023, marking a growth of 29.33% [4]. - Net profit attributable to shareholders was 13,050,671.23 yuan, down from 19,668,950.46 yuan in 2023, a decline of 33.65% [4]. - The net profit after deducting non-recurring gains and losses was 6,680,101.87 yuan, a decrease of 40.55% compared to 2023 [4]. - Operating cash flow net amount was 24,656,614.19 yuan, showing a significant increase of 1,176.30% year-on-year [4]. - Basic earnings per share were 0.12 yuan, down from 0.18 yuan in 2023, a decrease of 33.33% [4]. Revenue Breakdown - The pharmaceutical industry accounted for 314,245,411.71 yuan, representing 90.04% of total revenue, with a year-on-year growth of 32.97% [7]. - Revenue from the sterile production and contamination control equipment series was 164,121,071.60 yuan, a growth of 52.56% [5][7]. - Microbial detection technology series products generated 124,593,032.95 yuan, with a year-on-year increase of 17.15% [5][7]. - Organic analysis instruments series products contributed 25,531,307.16 yuan, up by 14.05% [5][7]. Geographic Performance - Domestic revenue was 324,965,505.54 yuan, accounting for 92.83% of total revenue, with a year-on-year growth of 31.49% [6][7]. - International revenue reached 25,032,747.49 yuan, reflecting an increase of 11.52% [6][7]. Future Strategy - The company aims to focus on the life and health industry, emphasizing technology-driven and leading development concepts [8]. - Plans include building a scientific R&D management system, accelerating the transition to smart manufacturing, and expanding overseas market share [8].